Breakthrough in Flu Vaccine Research: indigo’s Adjuvant Shows Promise in Humans
We are excited to announce a significant milestone in our ongoing efforts to revolutionize flu vaccination. A recent publication in the journal Vaccines has revealed promising results from the Phase 1 human trial of our innovative Carbohydrate Fatty Acid Monosulphate Ester (CMS) adjuvant.
Key Findings:
Safety Confirmed: The CMS adjuvant, previously untested in humans, has been shown to be safe and well-tolerated.
Effective at Lower Doses: When combined with just one-fifth of the standard flu vaccine dose, CMS induced immune responses comparable to full-dose vaccines without adjuvants.
Potential for Cost Reduction: These results suggest significant potential for antigen sparing, which could lead to more cost-effective vaccine production.
The study, titled "Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study," was conducted at the Center for Vaccinology (CEVAC) in Ghent, Belgium, and involved 60 participants aged 18-50.
What's Next?
Building on these encouraging results, the INDIGO consortium is now proceeding with Phase 1b trials in Ghent. These trials will expand our research to include populations aged 18-60 and those over 60, helping us better understand the vaccine's efficacy across different age groups.
This breakthrough has significant implications for global health, particularly in low-resource settings and potential pandemic scenarios. By enabling the production of more doses from the same amount of antigen, we could dramatically improve vaccine accessibility worldwide.
We at INDIGO are committed to advancing this promising technology and look forward to sharing more updates as our research progresses. Stay tuned for more exciting developments in our quest to make flu vaccines more effective and accessible for all.
For more detailed information, you can read the full article here.